Clinical Pharmacokinetics of Laninamivir, a Novel Long‐Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS‐8958, in Healthy Male Volunteers

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of clinical pharmacology

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/0091270009356297PMID 20145259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Developing new antiviral agents for influenza treatment: what does the future hold?

  2009cited by this paper
• Emergence and pandemic potential of swine-origin H1N1 influenza virus

  2009cited by this paper
• Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans

  2009cited by this paper
• Emergence of a novel swine-origin influenza A (H1N1) virus in humans.

  2009cited by this paper
• Prediction of the Pharmacodynamically Linked Variable of Oseltamivir Carboxylate for Influenza A Virus Using an In Vitro Hollow-Fiber Infection Model System

  2009cited by this paper
• CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract

  2009cited by this paper
• The risk of seasonal and pandemic influenza: prospects for control.

  2009cited by this paper
• Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans

  2009cited by this paper
• In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

  2009cited by this paper
• Recent Advances in Predictive Understanding of Respiratory Tract Deposition

  2008cited by this paper
• The potential impact of neuraminidase inhibitor resistant influenza

  2008cited by this paper
• In Vitro/In Vivo Comparisons in Pulmonary Drug Delivery

  2008cited by this paper
• CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity

  2008influential reference
• Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.

  2007cited by this paper
• Pharmacodynamic Evaluation of RWJ-270201, a Novel Neuraminidase Inhibitor, in a Lethal Murine Model of Influenza Predicts Efficacy for Once-Daily Dosing

  2001cited by this paper
• Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.

  2000cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections

  1997cited by this paper
• Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

  1997cited by this paper

• Revolutionizing Antiviral Therapeutics: Unveiling Innovative Approaches for Enhanced Drug Efficacy

  2024cites this paper
• Occurrence and environmental fate of anti-influenza drugs in a subcatchment of the Yodo River Basin, Japan.

  2024cites this paper
• Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”

  2024cites this paper
• The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs

  2023cites this paper
• Antiviral options and therapeutics against influenza: history, latest developments and future prospects

  2023cites this paper
• Fighting the flu: a brief review on anti-influenza agents

  2023cites this paper
• Antiviral Approaches against Influenza Virus

  2023cites this paper
• Antiviral drugs in wastewater are on the rise as emerging contaminants: A comprehensive review of spatiotemporal characteristics, removal technologies and environmental risks.

  2023cites this paper
• A Systematic Review of Clinical Pharmacokinetics of Inhaled Antiviral

  2023influential citation
• Antiviral Drugs in Influenza

  2022cites this paper
• Treatment of respiratory viral infections through inhalation therapeutics: Challenges and opportunities

  2022cites this paper
• Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.

  2021cites this paper
• Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes, influenza and other viral infections

  2020cites this paper
• How to Use Anti-influenza Drugs: Laninamivir Octanoate

  2020cites this paper
• Development of effective anti-influenza drugs: congeners and conjugates – a review

  2019cites this paper
• Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives

  2019cites this paper
• The selection pressure on the neuraminidase gene of influenza viruses isolated in Ukraine from 2009 to 2015

  2019cites this paper
• Efikasi, Mekanisme dan Resistensi Antiviral Neuraminidase Inhibitor dan Adamantane pada Avian Influenza (Efficacy, Mechanism and Antiviral Resistance of Neuraminidase Inhibitors and Adamantane against Avian Influenza)

  2019cites this paper
• Performance evaluation of the GastroPlusTM software tool for prediction of the toxicokinetic parameters of chemicals

  2018cites this paper
• Fate of new three anti-influenza drugs and one prodrug in the water environment.

  2017influential citation
• Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects

  2017cites this paper
• Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy.

  2016cites this paper
• Japanese Surveillance Systems and Treatment for Influenza

  2016cites this paper
• Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives

  2015cites this paper
• Mechanisms of resistance to neuraminidase inhibitors in influenza A viruses and evaluation of combined antiviral therapy

  2015cites this paper
• Optimizing antiviral therapy for influenza: understanding the evidence

  2015cites this paper
• Detection of Peramivir and Laninamivir, New Anti-Influenza Drugs, in Sewage Effluent and River Waters in Japan

  2015influential citation
• Clinical Pharmacokinetics of Inhaled Antimicrobials

  2015cites this paper
• Synthesis of Small Molecules for Diagnostics and Therapeutics of Influenza Virus

  2015cites this paper
• Identification of Bioactivating Enzymes Involved in the Hydrolysis of Laninamivir Octanoate, a Long-Acting Neuraminidase Inhibitor, in Human Pulmonary Tissue

  2014cites this paper
• From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?

  2014cites this paper
• Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

  2013cites this paper
• Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.

  2013cites this paper
• Influenza virus resistance to antiviral therapy.

  2013cites this paper
• Antiviral Drug Discovery

  2013cites this paper
• Pharmacokinetic Properties ofAnti‐Influenza Neuraminidase Inhibitors

  2013cites this paper
• Pharmacokinetic Mechanism Involved in the Prolonged High Retention of Laninamivir in Mouse Respiratory Tissues after Intranasal Administration of its Prodrug Laninamivir Octanoate

  2013cites this paper
• Influenza virus resistance to neuraminidase inhibitors.

  2013cites this paper
• Newer influenza antivirals, biotherapeutics and combinations

  2013cites this paper
• A Cutting‐Edge View on the Current State of Antiviral Drug Development

  2013cites this paper
• High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals

  2012cites this paper
• Intrapulmonary Distribution and Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Inhaled Administration of Its Prodrug, Laninamivir Octanoate, in Healthy Volunteers

  2012cites this paper
• Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).

  2012cites this paper
• Human viral diseases: what is next for antiviral drug discovery?

  2012cites this paper
• Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan

  2012cites this paper
• Human viral diseases: what is next for antiviral drug discovery?

  2012cites this paper
• Therapeutics Against Influenza

  2012cites this paper
• Enhanced anti-influenza agents conjugated with anti-inflammatory activity.

  2012cites this paper
• Cochrane Review: Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)

  2012cites this paper
• Antivirals in seasonal and pandemic influenza—future perspectives *

  2012cites this paper
• Influenza drug resistance.

  2011cites this paper
• Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza

  2011cites this paper
• Influenza Drug Resistance

  2011cites this paper
• Pharmacokinetics of Laninamivir after a Single Administration of its Prodrug, Laninamivir Octanoate, a Long-Acting Neuraminidase Inhibitor, Using an Easy-to-Use Inhaler in Healthy Volunteers

  2011influential citation
• Widespread use of neuraminidase inhibitors in Japan

  2011cites this paper
• Antivirals and resistance: influenza virus.

  2011cites this paper
• Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Laninamivir, a Novel Neuraminidase Inhibitor, After a Single Inhaled Dose of Its Prodrug, CS‐8958

  2011influential citation
• To Market, To Market—2010

  2011cites this paper
• Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition

  2011cites this paper
• Bioequivalence & Bioavailability

  2011influential citation
• Oseltamivir as Treatment for Children with Influenza Virus Infection

  2010cites this paper
• Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration

  2010cites this paper
• ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.

  2010cites this paper
• Long-Acting Neuraminidase Inhibitor Laninamivir Octanoate (CS-8958) versus Oseltamivir as Treatment for Children with Influenza Virus Infection

  2010cites this paper
• Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza

  2010cites this paper
• Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.

  2010cites this paper
• Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats

  2010cites this paper
• Single-use disposable dry powder inhalers for pulmonary drug delivery

  2010cites this paper
• In Vitro/In Vivo Comparisons in Pulmonary Drug Delivery

  2008cites this paper
• Neuraminidase inhibitors for preventing and treating influenza in children.

  2007cites this paper